However, some NMO patients are AQP4-IgG seronegative or have undetermined results, highlighting the need for reliable serum or CSF biomarkers to aid early diagnosis and improve MS treatment outcomes [14–16]. This evidence concerns the gene AQP4 and neuromyelitis optica.